Relmada Therapeutics (RLMD) Projected to Release Quarterly Earnings on Thursday

Relmada Therapeutics (NASDAQ:RLMD) is expected to be releasing its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to post earnings of ($0.1450) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Relmada Therapeutics Price Performance

Shares of NASDAQ RLMD opened at $4.14 on Tuesday. Relmada Therapeutics has a one year low of $2.65 and a one year high of $8.00. The firm’s 50 day simple moving average is $3.78 and its two-hundred day simple moving average is $5.32. The stock has a market capitalization of $441.61 million, a P/E ratio of -4.60 and a beta of 0.62.

Insider Transactions at Relmada Therapeutics

In related news, CFO Maged Shenouda purchased 120,200 shares of the firm’s stock in a transaction on Wednesday, September 9th. The shares were acquired at an average cost of $4.20 per share, with a total value of $504,840.00. Following the purchase, the chief financial officer directly owned 920,200 shares of the company’s stock, valued at approximately $3,864,840. This trade represents a 15.02% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 14.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relmada Therapeutics in a research note on Monday, September 14th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $12.00.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for central nervous system disorders. The company’s research has primarily targeted conditions with significant unmet medical needs, including major depressive disorder and other neuropsychiatric diseases.

Relmada’s lead investigational product is REL-1017, also known as esmethadone or dextromethadone. The orally administered compound is designed to modulate the N-methyl-D-aspartate (NMDA) receptor and has been studied as a potential adjunctive treatment for major depressive disorder in patients who do not respond adequately to standard antidepressants.